Back to Agenda
Session 4: Plenary – Bridging Gaps: Diversity, Equity, and Inclusion in Drug Development
Session Chair(s)
Marilyne Chamoun, MSC
Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau, Health Canada, Canada
Samar Darwish, MBA, MSC
Director, Drug Regulatory Affairs, Boehringer Ingelheim, Canada
Biological and social differences can impact the way that drugs function in different populations. Even when clinical trials include large and diverse samples, certain populations continue to be under-represented due to various reasons. This session will bring together the regulator, industry and other perspectives and will discuss challenges in ensuring equitable inclusion in clinical trials and potential solutions.
Learning Objective : - Describe Health Canada’s Sex and Gender Based Analysis + (SGBA+) strategy
- Identify challenges related to the inclusion of a diverse population in drug development that takes into account differences related to sex, gender, age, ethnicity and vulnerable populations
- Discuss strategies, innovative approaches to improve representation and increase diversity and equity in drug development
Speaker(s)
Alysha Croker, PHD
Director, Strategic and Horizontal Policy, Health Canada, Canada
Speaker
Richardae Araojo, PHARMD, MS
Associate Commissioner for Minority Health, Director, Office of Minority Health , FDA, United States
Speaker
Kaveeta Vasisht, DrMed, MD, PHARMD
Associate Commissioner for Women's Health, Director of the Office of Women’s Hea, FDA, United States
Speaker
Kim Fookes
Global Head, Diversity and Inclusion in Clinical Trials, Novartis Pharmaceuticals, United States
Speaker
Have an account?